Best b presentation on Myopathy Mortality Adane.pptx

Best b presentation on Myopathy Mortality Adane.pptx

• 1.
  Mortality in Idiopathic Inflammatory Myopathies(IIM) AdanePetros Internal Medicine 3rd year Resident April, 2021
• 2.
  A 44 yearsold right handed male Presented with Erythematous to violaceous papules over the extensor joints of the hand with no muscle complaint. P/E was pertinent for facial heliotrope rash and gottron papules. with No neurological deficit on examination. Case
• 3.
  Case 1
• 4.
  Which of thefollowing is true A. This patient has low risk for ILD in comparison with a patient with similar presentation and proximal muscle weakness B. Presence of either anti –jo-1 or anti- MDA5 antibody increases the risk of ILD in a DM patient C. DM has lower risk of malignancy and increased risk of ILD compared to PM patient D. Rhabdomyolysis is the commonest cause of death in such patients
• 5.
   Introduction andEpidemiology  Clinical features and causes  Management approach Outline of Presentation
• 6.
  716 newly diagnosedIIM matched in 1:10 with normal population Mortality 31% in IIM group vs 12% in general population in 10 years Mortality 9% in IIM group vs 1% in general population in 1 year Epidemiology Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study Gerd Cecilie Dobloug etal
• 7.
  Pathophysiology  Main causesof death  Respiratory disease  Malignancy  Disease of circulatory system  Connective tissue diseases  Infection
• 8.
  Pathophysiology  Risk factors Delay in treatment for six months after symptom onset  Greater weakness at presentation  The presence of dysphagia  Respiratory muscle weakness  Interstitial lung disease  Associated malignancy  Cardiac involvement
• 9.
  Pathophysiology  Type ofDM and PM  Anti synthetase syndrome  Amyopathic dermatomyositis  Anti-MDA-5 antibodies  Overlap syndromes
• 10.
  Pathophysiology  Risk forMalignancy  older age at disease onset  dysphagia  evidence of capillary damage on muscle biopsy  cutaneous necrosis  cutaneous leukocytoclastic vasculitis
• 11.
  Prevention and Management Careful surveillance of newly diagnosed patients with IIM for  Cancer,  Lung involvement, and  Heart involvement,  As well as careful monitoring of heart and lung function during the first year of follow-up  Disease activity scoring
• 12.
   Thank You
• 13.
   UpToDate online International Myositis Assessment and Clinical studies group network Harrison’s principle of internal medicine,20th ed  Review articles  Adams Principles of Neurology  Bradley’s Neurology References